"It is absolutely certain that each country, including the Russian Federation, should have several different vaccines. This is what we are doing today”, Popova told reporters, when asked to compare the vaccine from the Gamaleya Research Institute, which has already been registered, and another from the State Research Centre of Virology and Biotechnology Vector.
In July, Vector started clinical trials of its vaccine against COVID-19, which is expected to be registered in the fall.
Earlier in August, Russia registered the world’s first COVID-19 vaccine, named Sputnik V and developed by the Gamaleya Institute. The Russian Ministry of Health said that Sputnik V has undergone all the necessary checks and proven to be capable of building immunity against the virus.
Russian officials are currently in talks with a number of countries to seal production and distribution agreements.
